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Platelets play a central role in thrombosis, hemo-
stasis, and inflammation. We show that activated
platelets release inorganic polyphosphate (polyP),
a polymer of 60–100 phosphate residues that directly
bound to and activated the plasma protease factor
XII. PolyP-driven factor XII activation triggered
release of the inflammatory mediator bradykinin by
plasma kallikrein-mediated kininogen processing.
PolyP increased vascular permeability and induced
fluid extravasation in skin microvessels of mice.
Mice deficient in factor XII or bradykinin receptors
were resistant to polyP-induced leakage. PolyP initi-
ated clotting of plasma via the contact pathway.
Ablation of intrinsic coagulation pathway proteases
factor XII and factor XI protected mice from polyP-
triggered lethal pulmonary embolism. Targeting
polyP with phosphatases interfered with procoagu-
lant activity of activated platelets and blocked
platelet-inducedthrombosis inmice.Addition ofpolyP
restored defective plasma clotting of Hermansky-
Pudlak Syndrome patients, who lack platelet polyP.
The data identify polyP as a new class of mediator
having fundamental roles in platelet-driven proin-
flammatory and procoagulant disorders.
INTRODUCTION
In mammals, blood clotting involves both cellular and protein
components, provided by platelets and coagulation factors,
respectively. Upon vascular injury, platelets rapidly adhere and
aggregate to form a plug; simultaneously, coagulation factors
respond in a complex reaction cascade to form fibrin, whichstrengthens platelet clots (Furie and Furie, 2008; Mackman,
2008). It has become evident that platelets also contribute to
host responses to infection and inflammatory vascular pro-
cesses such as formation and extension of atherosclerotic
plaques (Ruggeri, 2002). Basic and clinical data suggest that
thrombosis and inflammation are intrinsically linked and share
several key mechanisms (von Hundelshausen and Weber,
2007; Wagner and Frenette, 2008).
In the original cascade/waterfall model of coagulation,
thrombin and fibrin formation is initiated by two distinct path-
ways, triggered by exposure of blood to a damaged vessel
wall (extrinsic) or to blood-borne (intrinsic) factors. The intrinsic
pathway of coagulation is initiated by factor XII (FXII), in a reaction
involving high molecular weight kininogen (HK) and plasma kalli-
krein (PK), collectively referred to as the plasma contact system.
Upon contact with anionic surfaces a conformational change
occurs in FXII zymogen, resulting in a small amount of active
FXII (FXIIa). FXIIa cleaves PK to generate active kallikrein, which
in turn reciprocally activates additional FXII (Colman, 2006). This
process triggers the intrinsic pathway of coagulation via FXIIa-
mediated activation of factor XI (FXI) and also liberates the
inflammatory mediator bradykinin (BK) by kallikrein-mediated
cleavage of HK (Gailani and Renne, 2007a). The binding of BK
to its B2 receptor (B2R) activates various intracellular signaling
pathways that dilate vessels, induce neutrophil chemotaxis,
and increase vascular permeability (Leeb-Lundberg et al., 2005).
FXII is activated in vitro by a variety of polyanionic surfaces,
such as kaolin, glass, ellagic acid, certain polymers, nucleotides,
sulfatides, misfolded proteins, and some types of collagen or
glycosaminoglycans (Muller and Renne, 2008). FXII activation
by kaolin (a silicate) is used to trigger the aPTT clotting assay
that is a standard laboratory measurement of plasma coagula-
tion. Despite its importance for in vitro clotting, FXII deficiency
is not associated with any hemorrhagic disorder in humans or
mice (Ratnoff and Colopy, 1955; Pauer et al., 2004) and is
considered to be redundant for normal hemostasis. ChallengingCell 139, 1143–1156, December 11, 2009 ª2009 Elsevier Inc. 1143
the dogma of the coagulation balance, mouse models indicate
a critical role of FXII in thrombosis. Deficiency of FXII attenuates
arterial thrombus formation and protects animals from ischemic
brain injury (Renne et al., 2005a; Kleinschnitz et al., 2006).
For >40 years platelets have been linked to the intrinsic pathway
(Castaldi et al., 1965), with activation promoting fibrin formation
in a FXII-dependent manner (Walsh and Griffin, 1981). These
findings suggest that FXII is activated on procoagulant platelets
but the mechanisms involved and the relevance of platelet-
driven procoagulant and proinflammatory reactions in vivo are
unclear (Furie and Furie, 2008).
Polyphosphate (polyP) is an inorganic, linear polymer of ortho-
phosphate units linked by phosphoanhydride bonds. PolyP is
abundant in nature and has been conserved throughout evolu-
tion. PolyP has been extensively studied in prokaryotes and
lower eukaryotes, where it functions in basic metabolism, in
stress responses, and as a structural component (Rao et al.,
2009). Dense granules of platelets contain polyP (Ruiz et al.,
2004). Synthetic polyP is a potent modulator of plasma clotting,
affecting the intrinsic pathway, the fibrinolytic system, factor V
activation, and fibrin structure (Smith and Morrissey, 2008a;
Smith et al., 2006). The in vivo relevance of polyP functions
remains to be established.
Using genetically altered mice and patient plasma, we show by
activating the plasma contact activation system that platelet polyP
is a procoagulant and proinflammatory mediator. PolyP repre-
sents the long sought ‘‘foreign’’ surface that triggers fibrin forma-
tion byactivated platelets linking primary tosecondary hemostasis
and critically contributing to ‘‘procoagulant’’ platelet activity.
Interrupting polyP-driven fibrin and BK generation interferes with
thrombosis and edema formation in vivo may present a new
paradigm to fight thromboembolic and inflammatory disease.
RESULTS
Activated Platelets Release PolyP
Platelet dense granules contain polyP (Ruiz et al., 2004). We
analyzed whether activated/procoagulant platelets release
polyP. Washed human platelets were stimulated with ADP,
thrombin receptor-activating peptide 6 (Trap6), collagen, or
thrombin, after which polyP was isolated from stimulated platelet
supernatants using an ion-exchange method previously used to
purify polyP from cell lysates (Kumble and Kornberg, 1995). It
was then separated by agarose-gel electrophoresis and
probed with toluidine blue (Figure 1A) and a more sensitive
DAPI-based fluorescent stain (Figure 1B) (Smith and Morrissey,
2007). Incubation of the extracted material with proteinase,
RNase, DNase, or glycosaminoglycan-cleaving enzymes did
not alter the staining patterns (not shown). In contrast, treatment
with phosphatase (Psp), which hydrolyzes polyP, completely
abolished the signal (Figures 1A and 1B, ‘‘thrombin+Psp’’).
Platelet polyP migrated in a similar manner to synthetic polyP
with mean chain lengths of 70 ± 16 (polyP70) phosphate units
and at higher mass than polymers of 20± 6 phosphates (polyP20).
We determined the chain length of platelet polyP using 31P-NMR.
The relative ratio of signal intensities of the phosphate end groups
(a-P, 10.2 ppm) versus central phosphates (b-P, 22.1 ppm)
yielded a mean chain length of platelet polyP of 80, consistent1144 Cell 139, 1143–1156, December 11, 2009 ª2009 Elsevier Inc.with its migration in the agarose matrix (Figure 1C). Our NMR
analysis indicated that the mean chain length of ‘‘polyP75’’ used
in previous studies (Ruiz et al., 2004; Smith et al., 2006) is 125
(Figure S1 available online). This polyP (termed polyP125, Figures
1A and 1B) migrated with higher molecular weight than platelet
polyP. Integration of all 31P signals revealed that >69% of total
inorganic phosphate released by platelets is polyP.
PolyP Activates the Contact System In Vitro
We analyzed whether platelet polyP could act as a surface for
FXII activation using the chromogenic substrate S-2302, which
is hydrolyzed by active FXII (FXIIa) (Figure 2A). Addition of polyP
(100 mg/ml) to human (or to murine, Figure S2A) platelet-free
plasma (PFP) generated FXIIa with similar kinetics and potency
as an identical concentration of kaolin. Treatment of polyP with
Psp before addition to plasma reduced polyP-driven FXIIa
generation in human and murine plasma in a time-dependent
manner. Psp digestion for >60 min completely abolished the
FXIIa-generating activity of polyP (Figures 2A and S2A), suggest-
ing that a critical polymer length is required to induce FXII
activation. Indeed, synthetic polyP of mean chain length %45
phosphate units failed to trigger FXII activation in plasma
(Figure S2B). To discriminate between polyP-mediated FXII
autoactivation and FXII activation by PK, we incubated purified
FXII and PK with polyP. PolyP was as efficient as dextran sulfate
(a strong contact activator; Colman, 2006) in supporting
PK-driven activation of FXII (Figure 2B). When autoactivation of
FXII was investigated without the addition of PK to the reaction,
polyP generated significant amounts of FXIIa compared to the no
surface control but was not as efficient as dextran sulfate
(Figure 2C). The ability of a molecule to trigger contact activation
relies on interactions of contact factors with the negatively
charged surface (Colman, 2006). A gel-shift assay demonstrated
direct binding of polyP to contact system factors (Figure 2D).
Electrophoretic mobility shifts indicated strong interaction of
polyP with both FXII and HK, whereas binding to PK and FXI
was minor. PolyP did not bind to antithrombin or albumin.
Zirconia beads coated with either polyP or albumin confirmed
specific and direct polyP binding to FXII, PK, HK, and FXI, with
FXII being the strongest polyP-interacting protein (Figure 2E).
PolyP Triggers Bradykinin Generation
We examined whether polyP stimulates BK release in human
plasma and observed complete cleavage of HK at concentra-
tions >1 mg/ml (Figure 3A). Consistently, BK concentration in
these samples was high (>750 ng/ml) but relatively low in
samples treated with buffer (31 ± 4 ng/ml) or %1 mg/ml polyP,
which was not sufficient to initiate HK processing (Figure 3B).
To confirm that the FXII/PK cascade mediated BK generation
from HK, we probed for the zymogens by western blotting and
found that polyP >1 mg/ml triggered complete PK and FXII acti-
vation with a slightly higher concentration (>2 mg/ml) resulting
in complete activation of plasma FXII (Figure 3A).
PolyP Initiates Bradykinin-Dependent Mechanism
In Vivo
To analyze whether polyP initiates contact system-mediated
capillary leakage via BK formation, we employed a Miles edema
Figure 1. Activated Platelets Secrete Long-Chain PolyP
Washed platelets (3.8 3 1013 platelets each) were stimulated with ADP (0.1 mM), Trap6 (0.2 mM), collagen (0.2 mg/ml), thrombin (2 U/ml), or buffer (‘‘w/o’’) and
polyP was isolated from the supernatants. PolyP was separated by agarose gel electrophoresis and stained with toluidine blue (A) or DAPI (B). Synthetic polyP
with mean chain lengths of 20 (polyP20), 70 (polyP70), or 125 (polyP125) phosphate units were loaded in lanes 1–3 as size standards. Purified material from
thrombin-stimulated platelets was incubated with Psp (0.05 U/mg polyP; ‘‘thrombin + Psp’’) prior to electrophoresis. Negatively charged chondroitin sulfate
(CS) confirmed specificity of staining. A DNA ladder as size standard is indicated on the left.
(C) 31P NMR spectrum of platelet polyP at 202.4 MHz. The terminal and internal phosphates of the polyP chain give signals at 10.2 (doublet, blue arrows) and
22.1 (red arrow) ppm, respectively; ratios of their intensities yielded a mean chain length of 80 for platelet polyP. Other phosphate species present are
monophosphate (0.0 ppm, 5 % of total platelet released phosphate), diphosphate (10.4 ppm, 13 %), cyclotriphosphate (21.4 ppm, 10 %), and ADP
(11.2 ppm, 3 %).model in genetically altered mice (Figures 4A–4F). In wild-type
(WT) animals, platelet polyP or synthetic polyP125 (10 mg each)
initiated leakage was increased 7.9- ± 0.8- and 7.4- ± 1.0-fold,
respectively, higher than vehicle alone (Figures 4A and 4G). BK
stimulation in WT mice increased leakage to 11.3- ± 1.5-fold
over vehicle (Figure 4A). To confirm that polyP induces vascular
leakage by releasing BK, we employed B2R-deficient (B2R/)
mice, which are protected from BK-driven edema formation
(Han et al., 2002). B2R/ mice were mostly resistant to polyP-
induced increase in permeability (polyP 1.1- ± 0.2-fold and
polyP125 1.1- ± 0.1-fold, Figures 4B and 4G). Similarly, BK failed
to induce a response inB2R/mice (1.1-±0.2-fold, not depicted)
whereas injection of histamine (100 mM) resulted in considerable
leakage (7.7- ± 1.3-fold compared to vehicle), confirming thatB2R/ mice are susceptible to edema formation via contact
system-independent pathways. Because FXII-independent
mechanisms for PK activation exist (Muller and Renne, 2008),
we analyzed polyP-triggered leakage in FXII-deficient mice
(FXII/), which are defective in contact system-driven BK forma-
tion (Pauer et al., 2004). FXII/ mice were almost completely
resistant to polyP-induced leakage, and the degree of edema
was not significantly different from the buffer-treated group (polyP
1.3- ± 0.2-fold and polyP125 1.2- ± 0.2-fold, n = 10, p > 0.05,
Figures 4C and 4G). BK-stimulated edema formation in FXII/
mice was similar to that observed in WT animals (10.4-± 1.3-fold).
Hereditary angioedema is characterized by recurrent attacks
of swelling owing to a deficiency of a functional C1 esterase
inhibitor (C1INH), which is the major plasma inhibitor for severalCell 139, 1143–1156, December 11, 2009 ª2009 Elsevier Inc. 1145
Figure 2. PolyP Triggers Contact Activation of Factor XII
(A) Human plasma was incubated with 100 mg/ml polyP (:) or kaolin (B). Platelet polyP was either untreated (0 min) or pretreated with Psp (0.05 U/mg polyP) for
10 ( ), 30 ( ), or 60 min ( ). Data are means ± standard deviation (SD), n = 5.
(B and C) Plasma-free activation of purified FXII (200 nM) was analyzed in the presence (B) or absence (C) of PK (0.5 nM). The mixture was stimulated with dextran
sulfate (-; 1 mg/ml), polyP (:; 5 mg/ml), or buffer (C). FXIIa concentrations were determined using S-2302 hydrolysis. Data are means ± SD, n = 4.
(D) Gel-mobility shift analyses of polyP binding to proteins. Purified FXI, FXII, PK, HK, antithrombin (AT), or albumin (ALB) were incubated with buffer (‘‘w/o‘‘) or
with increasing concentrations of polyP125 (0–100 mg) for 10 min, after which mixtures were resolved on a 10 % Tris-Glycine gel under native conditions and
stained for protein using Gel Code Blue.
(E) Protein binding to immobilized polyP. PolyP (left) or albumin (ALB, right) was coupled to zirconia (zirconium dioxide) beads. FXII, FXI, PK, or HK (5 mg each)
were incubated with the beads, after which the flow-through (‘‘FT’’) fraction was collected by centrifugation using mini-spin columns. The beads were washed
with a low-salt buffer (50 mM NaCl; ‘‘LS’’) followed by a high-salt buffer (1 M NaCl; ‘‘HS’’). Fractions were probed by western blotting with appropriate antibodies.
Starting material (‘‘SM’’) refers to the initial protein load added to the beads.complement proteases, FXIIa and PK (Zuraw, 2008). PolyP initi-
ated edema in C1INH null (C1INH/) animals that exceeded
levels in WT by >40% (polyP 11.8- ± 0.9-fold and polyP125
10.9- ± 0.8-fold, Figures 4D and 4G), whereas BK-induced
(11.0- ± 0.8-fold) tracer extravasation was similar to WT mice
levels (11.3- ± 1.5-fold).
Since congenital deficiency in B2R or FXII protects mice from
polyP-driven edema formation, pharmacological targeting of BK
signaling or formation should provide similar protection. To
address this hypothesis, we treated WT mice with the FXIIa
inhibitor H-D-Pro-Phe-Arg-chloromethylketone (PCK) (Kleinsch-
nitz et al., 2006), or with the B2R antagonist Icatibant (Icat), 5 min
prior to polyP application. PolyP was unable to induce leakage1146 Cell 139, 1143–1156, December 11, 2009 ª2009 Elsevier Inc.in WT mice pretreated with PCK (polyP 1.9- ± 0.4-fold and
polyP125 1.2- ± 0.2-fold, Figures 4E and 4G) or Icat (polyP
1.6- ± 0.2-fold, polyP125 1.1- ± 0.2-fold, Figures 4F and 4G).
BK function was blocked by Icat (1.2- ± 0.1-fold) but was inde-
pendent of FXII activity (9.6- ± 2.3-fold, Figure 4F).
BK is an important mediator in bacterial infections. Escherichia
coli that locally assemble contact system proteins on their
surface generate BK (Herwald et al., 1998). We analyzed bacte-
rial polyP for BK formation. PolyP was purified from E. coli, sepa-
rated by agarose-gel electrophoresis, and stained with toluidine
blue. Consistent with chain lengths of 100–1000 in E. coli
(Rao et al., 2009) the polymer migrated with an apparent
molecular weight of 10–100 kDa (Figure 4H). As little as 1 mg/ml
E. coli-derived polyP initiated contact activation with complete
cleavage of FXII, FXI, PK, and HK but not of low molecular weight
kininogen (LK) (Figure 4I); E. coli polyP potently triggered BK
generation (Figure 4J). Psp treatment of E.coli polyP abrogated
activation of the contact system, as detected by persistence
of zymogen forms (right lanes, Figure 4I) and low levels of BK
(28 ± 3 ng/ml, Figure 4J). Intraperitoneal (i.p.) application of polyP
(750 mg/g body weight) in WT mice induced strong writhing reac-
tions (a pain reaction) and decreased systemic arterial blood
pressure (109 ± 17 to 57 ± 39 mmHg, n = 10, survivors and
nonsurvivors); 9/10 mice died within 15 min of challenge
(Figure 4K). In contrast, FXII/ and B2R/ mice were protected
from polyP-induced hypotonic shock, writhing reaction, and
edema formation, with 8/10 and 7/10 animals (**p < 0.01 FXII/
or B2R/ versus WT), respectively, surviving.
PolyP Initiates the Intrinsic Pathway of Coagulation
in Plasma
To analyze the procoagulant activity of polyP, we incubated
human plasma with increasing concentrations of the polymer
(0.5–1000 mg/ml) and followed generation of FXIIa and activation
of its principal substrate in the intrinsic pathway of coagulation,
FXI, by western blotting (Figure 5A); we also quantified thrombin
generation (Figure 5B). PolyP R2 mg/ml triggered the conver-
sion of FXII and FXI to active proteases (as indicated by the
disappearance of the zymogen forms at 80 kDa, Figure 5A),
which correlated with polyP-triggered thrombin generation (Fig-
ure 5B). Digestion of polyP with Psp (0.05 U/mg polyP) impeded
the procoagulant activity of the polymer. Furthermore, we
compared polyP with kaolin for initiating thrombin formation in
plasma in real time using a fluorogenic thrombin substrate.
PolyP- and kaolin-driven thrombin generation had almost
identical kinetics, potency, and effects on total thrombin gener-
Figure 3. PolyP Activates the Kallikrein-
Kinin System
(A) PolyP-induced cleavage of FXII, PK, and HK
in plasma. Human plasma was incubated with
increasingconcentrationsofpolyP (0.5–1000mg/ml)
or buffer (‘‘w/o’’), then subjected to SDS-PAGE
and western blotting. Samples were probed with
antibodies against FXII, HK, and PK.
(B) PolyP-induced bradykinin release in plasma.
BK in polyP-incubated samples was quantified
by ELISA. Data are means ± SD, n = 4.
ation (Figure S2C). Preincubation of
polyP with Psp largely abolished
thrombin formation (ETP < 100 nM*min).
Addition of polyP to normal plasma but
not FXII-depleted plasma shortened
the clotting time in a dose-dependent
manner (Figure 5C). Clotting times in re-
calcified plasma triggered by synthetic
polyP125 and polyP1000 were similar to
kaolin, whereas polyP3-stimulated clot-
ting was similar to buffer control
(Figure S2D).
We analyzed tissue factor (TF)- and polyP-initiated clotting in
normal and FXII-deficient human plasma (Figure 5D). Application
of TF or polyP shortened the clotting time to 80 ± 6 and 78 ± 5 s,
respectively (untreatedplasma> 450s). PolyP addition toTF-stim-
ulated plasma further accelerated clotting (29 ± 5 s). The ability of
polyP to induce clotting in FXII-deficientplasma was impaired (590
± 35 s) compared to normal plasma, whereas TF-stimulated clot-
ting was unaffected (82 ± 2 s). Coapplication of polyP and TF to
FXII-deficient plasma further shortened clotting times slightly to
66 ± 3 s. Similar to human plasma, polyP induced clotting of WT
mouse plasma (74 ± 5 s) and accelerated TF-initiated clotting
(TF alone: 69± 5, TF and polyP: 54± 6 s). In FXII/ mouse plasma,
polyP had minor procoagulant activity (380 ± 42 s) and slightly
increased TF-initiated clotting (76± 5 versus 65± 4 s) (Figure S3A).
Also, downstream of FXII in the coagulation cascade, polyP
acts on proteins such as tissue factor pathway inhibitor (TFPI),
factor V (FV), and thrombin-activatable fibrinolysis inhibitor
(TAFI) (Smith et al., 2006). We analyzed the relative importance
of coagulation initiation via FXII versus acceleration of fibrin
formation via FV, TFPI, and TAFI for procoagulant polyP activity
(Figure 5E). Plasma was incubated with increasing polyP
concentrations (0–2 mg/ml, not sufficient to completely activate
FXII) in the presence or absence of active FV (FVa), PCI (a TAFI
inhibitor), or TFPI function-inhibiting antibodies. Adding exoge-
nous FVa to plasma accelerated clotting somewhat in the
absence of polyP. The procoagulant activity initiated by as little
as 0.5 mg/ml polyP, however, greatly exceeded polyP effects
on FV (Figure 5E). PolyP-driven clotting was largely independent
of anti-TFPI antibodies or PCI in this assay. PolyP completely
failed to trigger clotting in FXII-deficient plasma, indicating that
polyP effects on downstream coagulation proteins are not suffi-
cient to induce clotting without FXII activation. To specifically
analyze polyP-stimulated thrombin generation via the intrinsicCell 139, 1143–1156, December 11, 2009 ª2009 Elsevier Inc. 1147
Figure 4. PolyP Triggers Contact System-Mediated Bradykinin-Induced Edema in Mice
(A–F) Evans blue was intravenously (i.v.) infused as a tracer into the following: (A) WT mice, (B) B2R/ mice, (C) FXII/ mice, (D) C1INH/ mice, (E) PCK-infused
WT mice (8 mg/kg body weight), and (F) Icat-administered WT mice (175 mg/kg body weight). Dorsal skin edema formation was induced by intradermal injection of
50 ml normal saline (NaCl), BK (100 mM), platelet polyP (10 mg), or synthetic polyP125 (10 mg), respectively, and visualized by tracer extravasation after 30 min.
(G) Evans blue tracer from skin welts was extracted and quantified. Extravasated tracer is plotted as fold-increase of saline-induced signal in WT mice, to control
for inter-animal variability. Data are means ± SD, n = 10.
(H) Psp- (0.05 U/mg polyP, 30 min; ‘‘Psp’’) or buffer-treated E. coli polyP (‘‘w/o,’’ 2 mg/lane each) were separated by agarose gel electrophoresis and stained with
toluidine blue. A DNA ladder as size standard is indicated on the left.
(I and J) Murine plasma was incubated with Psp- (‘‘Psp’’) or buffer-treated (‘‘w/o’’) E. coli polyP (1 mg/ml, 30 min) and was probed for FXII, FXI, PK zymogen forms,
single-chain HK, and LK by western blotting. ELISA determined BK in samples supplemented with polyP. Means ± SD, n = 5.
(K) Mortality associated with intraperitoneal injection of E. coli polyP (750 mg/g body weight) in WT, FXII/, or B2R/ mice. For control, polyP was Psp digested
prior to infusion into WT animals (‘‘Psp’’). Animals alive in each group (n = 10) 30 min after challenge were considered as survivors.pathway, we blocked TF/FVII activity with 30 pM FVIIai. In
a dose-dependent fashion, polyP (0–4.8 mg/ml) increased total
and maximal thrombin (ETP, 569–971 nM*min, peak: 58–163 nM)
and shortened lag time (19.5–10.5 min) and time to peak
(24–14 min) (Figure 5F). In the absence of TF/FVII activity there
was no effect of polyP on thrombin generation in FXII-deficient
plasma (FXII-def., Figure 5F). In contrast, polyP accelerated
thrombin generation in FXII-deficient plasma stimulated with
TF (0.5 pM), although not by a large amount. PolyP did not
increase thrombin formation stimulated by TF in FXI-deficient
plasma (Figure 5G). Inhibition of neither TAFI activity nor TFPI
activity affected polyP-driven thrombin formation in the pres-
ence or absence of TF/FVII activity (not depicted), arguing
against direct effects of the polymer on these proteins.1148 Cell 139, 1143–1156, December 11, 2009 ª2009 Elsevier Inc.The originally described patient with FXII deficiency, John
Hageman, died from pulmonary embolism, which apparently
originated from a hemipelvis fracture-associated deep vein
thrombosis (Ratnoff et al., 1968). Does platelet polyP-initiated
FXII activation have implications for the embolic disease of
Mr. Hageman? We used thromboelastography in whole blood
to analyze clot firmness dependent on polyP and FXII activity
(Figure 5H). This method measures mechanical clot stability
(represented by the maximal amplitude of the curves in Fig-
ure S3B). Addition of polyP (5 mg/ml) increased clot firmness to
128% ± 4% versus untreated blood (100%). Pharmacological
targeting of FXII activity abolished polyP-mediated clot stabiliza-
tion (85% ± 3% versus 83% ± 3% in CTI-treated blood,
p > 0.05). As polyP does not affect factor XIII (FXIII) activity or
activation (Figure S3C), increased clot firmness conferred by the
polymer appears to be mediated by enhanced fibrin structures
(Smith and Morrissey, 2008a) and fibrin production (Figure 5F).
Deficiencies in Intrinsic Pathway Proteases Protect
Mice from PolyP-Induced Thrombosis
To analyze polyP for fibrin formation in vivo, we challenged WT
and FXII/ mice in a model of lethal pulmonary thromboembo-
lism (PE) by intravenous (i.v.) infusion of polyP (300 mg/g body
weight). All WT mice with the exception of a single animal
(14/15) died within 5 min of polyP application (Figure 6A). In
contrast, FXII/ mice were significantly protected from polyP-
induced PE, with 12 out of 15 FXII/ mice surviving the chal-
lenge for >30 min (**p < 0.01 FXII/ versus WT). To show that
the high level of survivors observed in FXII/ mice was a direct
result of defective polyP-driven FXII activation, we reconstituted
FXII null mice with human FXII (hFXII). Intravenous infusion of
human protein corrected the prolonged aPTT clotting time of
FXII-deficient murine plasma to normal values of WT mice
(28 ± 4 s) and restored susceptibility to lethal PE after polyP infu-
sion, with 12 out of 15 reconstituted animals dying (Figure 6A).
Pretreatment of polyP with Psp abolished its procoagulant
activity, with 14/15 mice surviving infusion of degraded polyP
(Figure 6B). The infestin4-based recombinant FXIIa-inhibitor
CSL829 (Schmidbauer et al., 2009) and PCK irreversibly inhibit
the amidolytic activity of FXIIa and PK-mediated activation of
FXII. CSL829 blocked polyP-driven FXII and consecutive FXI,
PK, and HK activation steps in plasma (Figure 6C). To test the
protective potential of FXIIa-inhibitors for polyP-driven throm-
bosis, WT mice were i.v. injected with CSL829 10 min prior to
polyP infusion, which prolonged the aPTT (48 ± 9 s) and signifi-
cantly protected mice from lethal PE (12 out of 15 survived;
**p < 0.01 versus WT, Figure 6A). PCK provided similar protec-
tion from polyP-triggered thromboembolism (12/15 survived,
not shown). Histological sections of lung tissue from polyP-
treated mice and counting of formed thrombi are shown in Fig-
ures 6D and 6E. While the majority of vessels were obstructed
in WT and hFXII-reconstituted FXII/ mice (dead and survivors),
virtually no thrombi were found in FXII/ mice and in WT animals
treated with FXIIa-inhibitors.
To analyze the mechanism of polyP-initiated PE in vivo we
used FXI/ mice and generated FXII//FXI/-double gene-
deficient animals. If the prothrombotic effect of polyP is medi-
ated through FXII activation and the consecutive activation of
FXI by FXIIa, then FXI/ and FXII//FXI/-deficient animals
should be protected from PE to the same extent as FXII/
mice (Figure 6A). Indeed, FXI and FXII/FXI-combined deficiency
conferred resistance to polyP-induced PE and both mouse
strains were largely protected from polyP challenge (11/15 and
13/15 survived; **p < 0.01 FXI/ and FXII//FXI/ versus
WT; p > 0.05 FXI/ and FXII//FXI/ versus FXII/). Targeting
B2R was shown to confer protection from arterial occlusion
induced by vascular injury (Gailani and Renne, 2007a). We
analyzed B2R/ mice in our PE model and found that almost
all (13/15) animals died, suggesting that BK is not required for
polyP-initiated PE. To confirm that polyP-initiated FXII activity
contributes to pathological thrombosis by the intrinsic pathway
of coagulation, we measured fibrin formation in lung tissuesCby quantitative immunoblot analysis of urea-insoluble tissue
extracts with the fibrin-specific antibody 59D8. Fibrin accumula-
tion was significantly reduced in the lungs of FXII/ and inhibitor
treated mice, compared to WT and reconstituted animals
(Figure 6F).
PolyP Initiates Fibrin Formation on Activated Platelets
To assess whether polyP may present the ‘‘foreign surface’’ that
initiates FXII-driven fibrin formation on platelets we determined
whether Psp, which efficiently degrades polyP (Figure 2A),
inhibits procoagulant platelet activity. Platelets of human
(Figure 7A) and mouse (Figure 7B) origin were stimulated with
calcium ionophore A23187 prior to recalcification. Platelet acti-
vation reduced clotting times in both species up to 3.2- and
4.2-fold compared to recalcification times in unstimulated
PRP. Addition of Psp prior to recalcification abrogated the pro-
coagulant activity of stimulated platelets resulting in similar
clotting times to unstimulated PRP. Psp did not alter the recalci-
fication time in PRP without platelet activation. Consistent with
our initial observation that clotting in A23187-stimulated PRP
depends on FXII (Renne et al., 2005a), clotting in FXII-deficient
PRP in response to the platelet activator was severely impaired
in the presence or absence of Psp (Figures S4A and S4B).
We analyzed whether platelet inhibitors prostaglandin E1
(PGE1) and N6,20-O-dibutyryladenosine 30,50-cyclic monophos-
phate (dBcAMP), which interfere with thrombin-stimulated
platelet activation, could inhibit the procoagulant activity of
Trap6-stimulated human (Figure 7C) and murine (Figure S4C)
platelets. PGE1, dBcAMP, or Psp did not alter recalcification
times in PRP without platelet activation. Trap6 reduced clotting
times 3.2-fold in human and 2.6-fold in mouse PRP. Addition
of Psp prior to recalcification interfered with Trap6-enhanced
clotting (1.2- in human and 1.4-fold in mouse PRP compared
to unstimulated control). Application of PGE1 and dBcAMP prior
to Trap6 reduced procoagulant platelet activity (1.9- and 1.6-fold
in human and 1.6- and 1.8-fold in murine PRP). Treatment with
Psp in addition to PGE1 or dBcAMP further reduced the
procoagulant activity of Trap6-treated platelets until clotting
times were no longer significantly different from unstimulated
PRP (p > 0.05).
To analyze polyP functions for pathological clotting driven by
stimulated platelets in vivo, we established a model of lethal
PE initiated by Trap6 infusion (Figure 7D). Trap6 activates plate-
lets and initiates polyP secretion (Figure 1), but Trap6 by itself
has no direct effect on the plasma coagulation cascade. Almost
all (13/15) WT mice died within 5 min after i.v. infusion of Trap6
(Figure 7D). In contrast, FXII/ mice were largely protected
from Trap6-induced lethal PE (13/15 survived). Consistent with
anticoagulant activity in human and mouse plasma (Figures 7C
and S4C), PGE1 and dBcAMP infusion into WT mice conferred
protection from PE; 10/15 mice treated with each inhibitor
survived the Trap6 challenge. Infusion of Psp prior to Trap6
application protected WT mice from lethal PE and 13 out of 15
animals survived the challenge for >30 min. Lung histology
from Trap6-treated mice confirmed PE (Figure S4D). Whereas
the vast majority of vessels was obstructed in WT animals, virtu-
ally no thrombi were found in FXII/ mice and in WT mice
treated with Psp. Endogenous Psp activity in plasma (Smithell 139, 1143–1156, December 11, 2009 ª2009 Elsevier Inc. 1149
Figure 5. PolyP Activates the Intrinsic Pathway of Coagulation in Plasma
(A) PolyP-induced cleavage of FXII and FXI in plasma. Plasma was incubated for 30 min at 37C with increasing concentrations of polyP (0.5–1000 mg/ml) and
analyzed by western blotting for zymogen forms of FXII and FXI. Untreated plasma (‘‘w/o’’) shows initial FXII and FXI levels.1150 Cell 139, 1143–1156, December 11, 2009 ª2009 Elsevier Inc.
et al., 2006) and on endothelial cells (Figures S5A and S5B)
degrades polyP slowly and polyP released from activated
platelets coincubated with endothelial cells (Figure S5D, inset)
initiated FXII-dependent thrombin and BK formation (Figures
S5C–S5E).
We further tested the importance of this concept for human
disease states. Hermansky-Pudlak Syndrome (HPS) is a rare,
complex hereditary disease (Gahl et al., 1998) in which a bleeding
diathesis results from platelet storage pool deficiency. HPS
patients have reduced or absent platelet dense granules, the
polyP storage site in platelets. We analyzed platelets isolated
from HPS patients for their ability to initiate clotting (Figure 7E).
Normal or HPS platelets were stimulated with Trap6 before
adding them to normal PFP. Supplementing plasma with normal
platelets resulted in a recalcification time of 280 s with no
additional shortening of the clotting time upon addition of exog-
enous polyP125 (10 mg/ml). Time to clot formation triggered by
stimulated HPS platelets was longer (425 s) and could be short-
ened to a ‘‘normal’’ time of approximately 300 s by addition of
polyP. These results indicate that the concentration of polyP
found in platelets is sufficient to trigger plasma coagulation,
but that a reduction in the normal range of these concentrations,
such as in HPS platelets, impairs the procoagulant potential of
activated platelets.
Cumulatively, these findings support the concept that inor-
ganic polyP is a new class of platelet-derived proinflammatory
and procoagulant mediator that exerts its effect by activation
of the FXII-driven contact activation system. PolyP initiates
fibrin formation on procoagulant platelets, linking primary to
secondary hemostasis.
DISCUSSION
Thrombosis may occur in the venous or arterial circulation,
causing PE or myocardial infarction and stroke, the most
common causes of death in the developed world (Mackman,
2008). Platelets play a pivotal role in vascular occlusive disease
(Furie and Furie, 2008; Ruggeri, 2002). These anucleate cells
contribute to fibrin formation and inflammation leading to the
concept of ‘‘procoagulant platelet activity.’’ This study demon-
strates that the inorganic polymer, polyP, which is secreted
upon platelet activation, is responsible for platelet-driven fibrin
formation and vascular leakage. PolyP mediates its effects by
activating the FXII-driven contact activation system that is
conserved in humans and mice (Ponczek et al., 2008). PolyP-triggered mechanisms are highly similar in both species (Figures
2, 5, 7, S2, S3, and S4). PolyP links platelet plug formation
(primary hemostasis) and fibrin generation (secondary hemo-
stasis). PolyP functions are not limited to thrombus formation
but also contribute to platelet-driven capillary leakage, which is
a hallmark of inflammatory reactions.
Using FXII-deficient mice we demonstrated that FXII activity
has an essential function for thrombus formation (Kleinschnitz
et al., 2006; Renne et al., 2005a). Severe deficiency in the clotting
factor (<10 % plasma level) impaired the stability of the growing
thrombus without interfering with fibrin formation at wound sites.
During pathological clotting, FXII operates through the intrinsic
pathway as FXI- and FXII/FXI-double gene-deficient mice are
similarly protected from thrombus formation (Renne et al.,
2005a; Wang et al., 2006). The decisive role of the intrinsic
pathway of coagulation for thrombosis is not restricted to mouse
models. Targeting FXI interferes with thrombosis in baboons
(Tucker et al., 2009) and severe deficiency of FXI is associated
with a reduced risk of ischemic stroke (Salomon et al., 2008).
Together these data challenge the current dogma of a coagula-
tion balance with normal hemostasis (fibrin formation at a site of
vessel injury) and thrombosis representing two sides of the same
coin. Fibrin-generating mechanisms that operate during patho-
logical thrombus formation involve pathways distinct from those
that are active during hemostasis (Gailani and Renne, 2007b).
The importance of the intrinsic pathway for thrombosis in
humans remains less clear compared to animal models since
individuals with severe deficiency of contact system proteases
are rare (Gailani and Renne, 2007a). Defective thrombus stability
in FXII/ mice (Renne et al., 2005a), reports of pulmonary
emboli in humans with congenital FXII deficiency (Mangal and
Naiman, 1980; Ratnoff et al., 1968), and reduced clot firmness
in FXIIa-inhibited blood (Figure 5H) raise an intriguing hypoth-
esis. Severe FXII deficiency interferes with thrombus propaga-
tion apart from the vessel wall and provides thromboprotection
(Gailani and Renne, 2007a, 2007b). However, FXII deficiency
may also have adverse effects. As in the case of John Hageman,
thrombi may develop under some circumstances by FXII-
independent mechanisms, especially when thrombosis is driven
by massive TF exposure. These thrombi are unstable (Figure 5H)
and easily embolize as revealed by intravital microscopy (Renne
et al., 2005a). FXII levels and overall mortality and death from
cardiovascular disease have a peculiar bell-shaped correlation;
mortality of patients with severe FXII deficiency was similar to
that of individuals having 100% FXII plasma levels (Endler(B) Thrombin generation in plasma incubated with buffer alone (,), 100 mg/ml kaolin (B), or platelet polyP ( ; ‘‘polyP’’), synthetic polyP125 (:), platelet polyP
treated with Psp prior to addition of plasma ( ; ‘‘polyP+Psp’’). Data are means ± SD, n = 5.
(C) Plasma clotting times. PolyP was added to normal plasma (C) or FXII-immunodepleted plasma (:) at a range of concentrations (0–5 mg/ml), with clot forma-
tion quantified as the half-maximal change in turbidity at 405 nm. Data are means ± SD, n = 3.
(D) Recalcification clotting times in normal (white columns) and FXII-deficient human plasma (black columns) incubated with TF (1 pM), polyP (3 mg/ml), TF and
polyP (1 pM and 3 mg/ml), or buffer (w/o). Data are means ± SD, n = 5.
(E) Recalcification clotting times triggered by polyP (0–2 mg/ml) in FXII-deficient plasma (FXII-def.,A) and normal human plasma (NP) supplemented with FVa
(4 nM,;), aTFPI antibody (10 mg/ml,,), or PCI (30 mg/ml,B). Means ± SD, n = 3.
(F–H) Real-time thrombin generation: (F) PolyP (0; 1.2; 4.8 mg/ml) triggered thrombin formation in plasma preincubated with an extrinsic pathway inhibitor FVIIai.
PolyP (4.8 mg/ml) failed to generate thrombin in FVIIai-treated, FXII-deficient plasma (FXII-def.). (G) Thrombin generation triggered by TF in FXII-deficient (red),
FXI-deficient (blue), and normal plasma (green) in the absence (dashed lines) or presence of polyP (solid lines, 4.8 mg/ml). (H) Maximum clot firmness assessed by
thromboelastography: Clot firmness in polyP (5 mg/ml), CTI (100 mg/ml), or polyP plus CTI-treated whole blood relative to untreated samples (100 %). Data are
means ± SD, n = 5.Cell 139, 1143–1156, December 11, 2009 ª2009 Elsevier Inc. 1151
Figure 6. PolyP Triggers Thrombosis In Vivo
(A and B) Survival times following polyP challenge. (A) Pulmonary thromboembolism was induced by i.v. infusion of platelet polyP (300 mg/g body weight) in WT
mice, FXII/ mice, FXII/ mice reconstituted with human FXII (‘‘hFXII,’’ 2 mg/g body weight), WT mice infused with FXIIa inhibitor CSL829 (15 mg/g body weight),
FXI/ mice, FXII- and FXI-gene double-deficient (‘‘FXII//FXI/‘‘) mice, or B2R/ mice. Mortality was assessed in each group (n = 15); animals still alive 30 min
after challenge were considered survivors. (B) PolyP was Psp digested (0.05 U/mg polyP) prior to infusion into WT animals and survival was analyzed as in (A).
(C) Plasma supplemented with CSL829 (150 mg/ml) or buffer (‘‘w/o’’) was incubated with polyP (500 mg/ml) for 30 min and analyzed by western blotting for
zymogen FXII, FXI, PK, and HK.
(D) Hematoxylin and eosin-stained sections of lungs of WT, FXII/, CSL829 infused WT, and hFXII reconstituted FXII/ mice 30 min after polyP administration
(bar = 100 mm).
(E) Thrombi per visual field were counted at 103 magnification from sections such as those in (D). Data are mean ± SD for 100 fields.
(F) Accumulation of fibrin in lung tissue of polyP-treated WT, FXII/, CSL829 pretreated WT, and reconstituted FXII/ mice. Fibrin formation 30 min after polyP
challenge was analyzed by western blotting.1152 Cell 139, 1143–1156, December 11, 2009 ª2009 Elsevier Inc.
Figure 7. Targeting PolyP Blocks Platelet Procoagulant Activity In Vitro and Thrombosis In Vivo
(A and B) Recalcification clotting times were determined in platelet-rich (A) human or (B) WT mouse plasma stimulated with A23187 (5 mM) in the presence (+) or
absence () of Psp (10 U/ml). Reductions in clotting times are given relative to untreated plasma. Data are means ± SD, n = 6.
(C) Recalcification clotting times were determined in Trap6 (30 mM) stimulated human platelet-rich plasma in the presence (+) or absence () of PGE1 (5 mM),
dBcAMP (0.5 mM), and Psp (10 U/ml). Reductions in clotting times are given relative to untreated PRP. Data are means ± SD, n = 6.
(D) Mortality associated with i.v. injection of 0.7 mg/g body weight Trap6 in WT mice; WT mice i.v. infused with PGE1 (0.85 mg/g body weight ‘‘WT+PGE1’’) or
dBcAMP (100 mg/g body weight ‘‘WT+dBcAMP’’); FXII/ mice; and WT mice injected i.v. with Psp (15 U/g body weight; ‘‘WT+Psp’’) before Trap6 challenge.
Thirteen of Fifteen WT mice died within 10 min of challenge. In contrast WT animals injected with PGE1 or dBcAMP, FXII/ and Psp-treated WT mice were signif-
icantly protected from lethal pulmonary embolism induced by Trap6; 10/15, 10/15, 13/15, and 13/15, respectively, survived for >30 min each (WT+PGE1,
WT+dBcAPMP, FXII/, and WT+Psp versus WT, p < 0.01, n = 15 per genotype).
(E) PolyP ‘‘rescues’’ defective fibrin formation in Hermansky-Pudlak Syndrome patients. Human platelets were isolated from healthy blood donors (control) and
from patients with Hermansky-Pudlak Syndrome (HPS) and stimulated for 10 min at 37C with Trap6 (50 mM) and collagen (10 mg/ml). Recalcification clotting
times in normal plasma on addition of either normal (control) or HPS platelets (HPS, 1.53 107) in the absence (open bars) or presence (closed bars) of additional
synthetic polyP125 (10 mg/ml) are shown. The graph shown is representative of three different experiments performed on different HPS and normal individuals.et al., 2007), indicating that thromboprotection from arterial
thrombosis is counterbalanced by other mechanisms in FXII-
deficient individuals. PolyP appears to contribute to thrombus
formation via increasing fibrin production in an FXII-dependent
manner (Figure 6F) and the stability of the fibrin structure (Smith
and Morrissey, 2008a).
PolyP is a ‘‘foreign’’ surface that is not present under ‘‘normal’’
nonactivated conditions. We did not observe polyP release from
stimulated endothelial cells, smooth muscle cells, E. coli, or
fibroblasts. Although these cells contain polyP that could be
liberated from disintegrating cells following injury, the polymer
apparently does not significantly contribute to fibrin formation
under these conditions since FXII-deficient individuals do notbleed excessively. Either the endothelial polyP concentration is
not sufficient to initiate the contact pathway, or yet unknown
regulatory mechanisms interfere with polyanion-driven FXII
activation at the vessel wall. RNA, which activates FXII and is
liberated from disintegrating cells, is prothrombotic but does
not contribute to hemostatic mechanisms (Kannemeier et al.,
2007). Some contact activators, e.g., misfolded proteins, specif-
ically trigger BK formation (Maas et al., 2008) but do not initiate
fibrin formation. Remarkably, patients with hereditary angioe-
dema, who suffer from increased BK formation, do not have an
increased thrombotic risk (Zuraw, 2008). The selective activation
of the FXII-driven cascade suggests that delicate regulatory
mechanisms of the contact system may exist that involve cellCell 139, 1143–1156, December 11, 2009 ª2009 Elsevier Inc. 1153
type-specific FXIIa effects (Renne et al., 2005b) and FXIIa prote-
olysis products (Schmaier, 2008).
Besides its importance for endogenous thrombus formation,
synthetic polyP may be used as a hemostatic agent to reduce
blood loss at sites of injury or during surgical interventions. PolyP
potently generates fibrin and its procoagulant activity is based
on two principal mechanisms. The polymer initiates fibrin forma-
tion via activating FXII and accelerates downstream procoagu-
lant reactions involving FV, TAFI, and TFPI (Smith et al., 2006).
Application of polyP has been shown to promote clot formation
in plasma from hemophilia A and B patients (who are deficient in
coagulation factor VIII or IX, respectively) (Smith and Morrissey,
2008b). In such plasmas, procoagulant activities of polyP were
additive to those of a recombinant form of activated factor VII
(rFVIIa), indicating that polyP-mediated fibrin formation is inde-
pendent of the rFVIIa-driven extrinsic pathway.
FXIIa may initiate several protease cascades in plasma, such
as the kallikrein-kinin system, the intrinsic pathway of coagula-
tion, and the complement and fibrinolytic systems (Gailani and
Renne, 2007a). Preformed FXIIa has been demonstrated to
induce leakage in skin microvessels in a BK-dependent manner
in mice (Renne et al., 2005b). Contact system-mediated kinin
release is a critical component of E. coli-induced sepsis and
septic shock (Herwald et al., 1998). It is not precisely known
how these bacteria initiate BK formation, but E. coli contain
high amounts of polyP (Rao et al., 2009), which readily activates
the contact system (Figure 4). One can speculate that disinte-
grating bacteria may release the polymer, which could activate
FXII and initiate BK-mediated leukocyte chemotaxis, pain sensa-
tions, and leakage (Leeb-Lundberg et al., 2005). FXIIa can initiate
the classical complement system that generates C3a and C5a
generation, which increase permeability in host-defense reac-
tions (Ghebrehiwet et al., 1981). Edema formation in polyP-
activated B2R null mice is largely impaired (Figure 4B), indicating
that BK signaling is essential for polyP-initiated angioedema and
the complement system or that any other FXIIa-driven cascades
are not sufficient to increase vascular permeability in response to
polyP. Consistently, genetic ablation of B2R in mice or pharma-
cological blockade of B2R in patients restores elevated vascular
permeability conferred by hereditary deficiency of C1INH (Han
et al., 2002; Zuraw, 2008).
Platelet activation triggers initiation and propagation of the
complement system (Del Conde et al., 2005). PolyP released
from activated platelets might therefore contribute to these
responses by generating FXIIa. In addition to being anti-throm-
botic (Figure 7), phosphatase may serve as a potent anti-inflam-
matory agent in reducing FXIIa-driven complement and BK
effects, with possible implications for acute and chronic inflam-
matory responses such as atherosclerosis, rheumatoid arthritis,
and inflammatory bowel disease, and also in the progression of
malignancies and in immune responses to bacteria. We focused
on polyP-driven acute BK effects in complex inflammatory reac-
tions. On cell surfaces free BK is rapidly degraded with a half-life
of <30 s (Renne et al., 2005b). Hormone binding to the constitu-
tively expressed B2R results in rapid internalization and
agonist-induced receptor desensitization thereby terminating
BK activity. BK signaling upregulates expression of IL-1b
and TNF-a. In turn, the cytokines induce expression of pharma-1154 Cell 139, 1143–1156, December 11, 2009 ª2009 Elsevier Inc.cological distinct kinin receptors, B1R. B1R are not normally
expressed but are induced selectively during injury. Activation
of B1R produces a proinflammatory profile similar to that of
B2R activation but also stimulates inflammatory cell accumula-
tion, which further amplifies cytokine production. As B1R do
not undergo agonist-induced desensitization, cytokines switch
kinin signaling from acute B2R-mediated effects to subacute
and chronic inflammatory response mediated by B1R (Leeb-
Lundberg et al., 2005).
In summary, we have shown that polyP triggers fibrin forma-
tion and capillary leakage by activated platelets in an FXII-
dependent manner. These findings establish inorganic polyP
as a heretofore unrecognized target for intervention of inflamma-
tory and thromboembolic diseases.
EXPERIMENTAL PROCEDURES
Extraction of PolyP
PolyP was purified from platelet concentrates of healthy volunteers that had
donated to the blood bank of Wu¨rzburg University Hospital, Germany. Washed
platelets were adjusted to 7.5 3 1011 platelets/ml in New Tyrode’s buffer
(145 mM NaCl, 5 mM KCl, 1 mM MgSO4, 0.5 mM Na2HP04, 5.5 mM glucose,
10 mM HEPES, pH 7.4, 0.35 % bovine serum albumin, pH 7.4) before activa-
tion with thrombin (2 U/ml) (Roche), Trap6 (0.2 mM) (Bachem) and collagen
(0.2 mg/ml) (Nycomed) for 1 min, or ADP (0.1 mM) (Sigma-Aldrich) for 5 min
at 37C. Supernatants were immediately collected by two centrifugation steps
at 3000 3 g for 15 min at 4C. An anion exchanger-based procedure was
employed (Kumble and Kornberg, 1995) with minor modifications to extract
polyP from platelets. Briefly, supernatants were incubated with proteinase K
(750 mg/ml, 37C, 1 hr) and extracted with a 1:1 phenol/chloroform mixture.
The aqueous phase was combined with extracts from the phenol layer in
50 mM Tris-HCl, pH 7.5, 10 mM EDTA, and again chloroform extracted. PolyP
was precipitated from the extracts with barium acetate (0.1 M) at pH 4.5 with
subsequent incubation for 4 hr at 4C and centrifugation at 14000 3 g for
30 min. The polyP precipitates were transformed to soluble state by adding
ion-exchange resin Dowex 50W 3 8 in NH4
+ form (SERVA Electrophoresis,
Heidelberg, Germany). The mixture was incubated on a shaker for 10 min
and then centrifuged at 100003 g for 30 min. The supernatant was incubated
with Benzonase (350 mg/ml) and chondroitinase ABC/heparitinase (5 U each)
for 5 hr. The reaction mixture was extracted with phenol/chloroform as
described above and polyP was isolated by evaporation. Yield was 20 mg
polyP from 3.7 3 1013 platelets.
PolyP were isolated from E. coli strain BL21, which were grown to an OD600
of 2.5 in LB-medium within 8 hr. Cells were pelleted and lysed in buffer (50 mM
Tris, 1 M Urea, 0.1 % SDS, 10 mM EDTA), suspension was sonicated on ice for
3 3 10 s bursts, and polyP was purified as described above. One milligram
polyP was purified from a 100 ml culture.
Activation of the Intrinsic Pathway In Vitro
Human citrate-anticoagulated plasma was incubated with Ca2+-saturated
polyP (0.5–1000 mg/ml) for 30 min at 37C. The reaction was stopped by the
addition of reducing La¨emmli buffer containing 4% (w/v) SDS. 0.2 ml plasma
per lane was analyzed by western blotting as described (Renne et al.,
2005b). BK plasma concentrations were quantified with MARKIT-M-Bradyki-
nin ELISA (Dainippon Pharmaceutical, Osaka, Japan). Activation of purified
FXII (200 nM) by kallikrein (0.5 nM) was analyzed by incubating at 37C in
the presence of either dextran sulfate (1 mg/ml), polyP125 (5 mg/ml), or buffer
alone (20 mM HEPES, pH 7.4, 100 mM NaCl; HBS). Reactions were stopped
at various times (0–60 min) in HBS buffer containing polybrene (5.5 mg/ml)
and soy trypsin inhibitor (100 mg/ml). Activity was quantified using a chromo-
genic substrate for FXIIa (200 nM, Bachem) and read against a standard curve
of purified FXIIa for 60 min at 405 nm in a VERSAmax microplate reader
(Molecular Devices). Autoactivation of FXII (200 nM) was analyzed in a similar
manner with addition of surfaces but in the absence of kallikrein.
PolyP-Induced Pulmonary Thromboembolism
Mice were anesthetized by i.p. injection of 2,2,2-tribromoethanol and
2-methyl-2-butanol (0.15 ml/10 g of body weight from a 2.5 % solution), and
polyP (300 mg/g body weight in NaCl) was slowly injected into the inferior
vena cava. Alternatively, Trap6 (0.7 mg/g body weight) was infused. In some
experiments, mice were injected i.v. with Psp (15 U/g body weight) before
the challenge. Animals still alive after 30 min were considered survivors.
Skin Vascular Leakage Assay
Stimulus-triggered leakage of skin microvessels was analyzed with a Miles
assay. Briefly, anesthetized mice were retro-orbitally injected with 10 ml/g
body weight 0.25 % Evans blue solution; 5 min later, 50 ml saline (negative
control), BK (positive control, 100 mM), or platelet-derived or synthetic polyP125
were intradermally injected in the dorsal skin of mice. After 30 min, the animals
were sacrificed and the skin was removed and photographed. Skin sam-
ples were excised and the Evans blue dye was extracted by incubation in N,
N-dimethyl formamide overnight at 55C. After centrifugation at 20000 3 g
for 60 min, the supernatant was collected and the concentration of the
extracted dye was determined by fluorescence spectroscopy.
NMR Analysis
A sample of commercial polyP125 (25 mg) (Sigma-Aldrich) and a sample of
lyophylized lysate (10 mg) were dissolved in heavy water (D2O) and the
31P
NMR spectra recorded at 202.4 MHz and 25C using a Bruker Avance
500 NMR spectrometer. Pulse delay and repetition time were set at 0.03 and
100 s, respectively, to ensure correct signal integration. The content of the
various species was then calculated directly from the signal intensities.
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